These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 23977103)

  • 1. Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.
    Takakuma K; Ogo N; Uehara Y; Takahashi S; Miyoshi N; Asai A
    PLoS One; 2013; 8(8):e71646. PubMed ID: 23977103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-Based Multiplexed Assay for Identifying SH2 Domain Antagonists.
    Asai A; Takakuma K
    Methods Mol Biol; 2017; 1555():351-356. PubMed ID: 28092042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and Purification of Soluble STAT5b/STAT3 Proteins for SH2 Domain Binding Assay.
    Asai A; Takakuma K
    Methods Mol Biol; 2017; 1555():163-172. PubMed ID: 28092032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high-throughput assay for signal transducer and activator of transcription 5b based on fluorescence polarization.
    Müller J; Schust J; Berg T
    Anal Biochem; 2008 Apr; 375(2):249-54. PubMed ID: 18258175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors.
    Cerulli RA; Shehaj L; Tosic I; Jiang K; Wang J; Frank DA; Kritzer JA
    Bioorg Med Chem; 2020 Jun; 28(12):115542. PubMed ID: 32503696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
    Zhao W; Jaganathan S; Turkson J
    J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe growth deficiency is associated with STAT5b mutations that disrupt protein folding and activity.
    Varco-Merth B; Feigerlová E; Shinde U; Rosenfeld RG; Hwa V; Rotwein P
    Mol Endocrinol; 2013 Jan; 27(1):150-61. PubMed ID: 23160480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
    Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
    Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
    Furtek SL; Matheson CJ; Backos DS; Reigan P
    Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An SH2 domain model of STAT5 in complex with phospho-peptides define "STAT5 Binding Signatures".
    Gianti E; Zauhar RJ
    J Comput Aided Mol Des; 2015 May; 29(5):451-70. PubMed ID: 25752764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical probes that competitively and selectively inhibit Stat3 activation.
    Xu X; Kasembeli MM; Jiang X; Tweardy BJ; Tweardy DJ
    PLoS One; 2009; 4(3):e4783. PubMed ID: 19274102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
    Resetca D; Haftchenary S; Gunning PT; Wilson DJ
    J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The STAT5b Linker Domain Mediates the Selectivity of Catechol Bisphosphates for STAT5b over STAT5a.
    Gräb J; Berg A; Blechschmidt L; Klüver B; Rubner S; Fu DY; Meiler J; Gräber M; Berg T
    ACS Chem Biol; 2019 Apr; 14(4):796-805. PubMed ID: 30835430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
    Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
    Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of STAT proteins on growth hormone-mediated IGF-I gene expression.
    Varco-Merth B; Rotwein P
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E847-55. PubMed ID: 25205818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
    Park IH; Li C
    J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
    Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
    J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
    Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
    PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase.
    Ram PA; Waxman DJ
    J Biol Chem; 1997 Jul; 272(28):17694-702. PubMed ID: 9211920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.
    Shao S; Yu R; Yu Y; Li Y
    J Mol Model; 2014 Aug; 20(8):2399. PubMed ID: 25098340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.